English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/103612
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice

AuthorsLorrio, Silvia; Romero, Alejandro ; González-Lafuente, Laura; Lajarín-Cuesta, Rocío; Martínez-Sanz, Francisco J.; Estrada, Martín ; Samadi, Abdelouahid ; Marco-Contelles, José ; Rodríguez-Franco, María Isabel ; Villarroya, Mercedes; López, Manuela G.; Ríos, Cristobal de los
KeywordsAlzheimer’s disease
Ser/Thr phosphatases
Issue Date2013
PublisherAmerican Chemical Society
CitationACS Chemical Neuroscience 4: 1267- 1277 (2013)
AbstractITH12246 (ethyl 5-amino-2-methyl-6,7,8,9-tetrahydrobenzo[b][1,8] naphthyridine-3-carboxylate) is a 1,8-naphthyridine described to feature an interesting neuroprotective profile in in vitro models of Alzheimer's disease. These effects were proposed to be due in part to a regulatory action on protein phosphatase 2A inhibition, as it prevented binding of its inhibitor okadaic acid. We decided to investigate the pharmacological properties of ITH12246, evaluating its ability to counteract the memory impairment evoked by scopolamine, a muscarinic antagonist described to promote memory loss, as well as to reduce the infarct volume in mice suffering phototrombosis. Prior to conducting these experiments, we confirmed its in vitro neuroprotective activity against both oxidative stress and Ca2+ overload-derived excitotoxicity, using SH-SY5Y neuroblastoma cells and rat hippocampal slices. Using a predictive model of blood-brain barrier crossing, it seems that the passage of ITH12246 is not hindered. Its potential hepatotoxicity was observed only at very high concentrations, from 0.1 mM. ITH12246, at the concentration of 10 mg/kg i.p., was able to improve the memory index of mice treated with scopolamine, from 0.22 to 0.35, in a similar fashion to the well-known Alzheimer's disease drug galantamine 2.5 mg/kg. On the other hand, ITH12246, at the concentration of 2.5 mg/kg, reduced the phototrombosis-triggered infarct volume by 67%. In the same experimental conditions, 15 mg/kg melatonin, used as control standard, reduced the infarct volume by 30%. All of these findings allow us to consider ITH12246 as a new potential drug for the treatment of neurodegenerative diseases, which would act as a multifactorial neuroprotectant.
Identifiersdoi: 10.1021/cn400050p
issn: 1948-7193
e-issn: 1948-7193
Appears in Collections:(IQOG) Artículos
(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.